Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Gefitinib sustained-release implantation agent for curing entity tumour

A slow-release implant, gefitinib technology, applied in the field of medicine, can solve the problems of systemic toxicity and side effects limiting clinical application, limiting clinical application, cardio-liver-pulmonary system toxicity, etc.

Inactive Publication Date: 2008-05-14
JINAN SHUAIHUA PHARMA TECH
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its extensive application often causes severe myelosuppression and heart, liver and lung systemic toxicity, which greatly limits its clinical application.
[0005] Although gefitinib alone or in combination with other anticancer drugs may have certain effects on certain tumors, the systemic side effects caused by conventional administration limit its clinical application.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gefitinib sustained-release implantation agent for curing entity tumour
  • Gefitinib sustained-release implantation agent for curing entity tumour

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Put the weighed (90mg) sustained-release excipient (polylactic acid (PLA) with a molecular weight of 15000-30000) into the container, add a certain amount of organic solvent to dissolve and mix (subject to full dissolution), then add 10mg For Fitinib, re-shake well and dry in vacuo to remove organic solvents. The dried solid composition is shaped immediately, subpackaged and sterilized by radiation to obtain a slow-release implant containing 10% gefitinib. The release time of the sustained-release implant in physiological saline in vitro is 20-25 days, and the release time in mouse subcutaneous is 22-26 days.

Embodiment 2

[0087] Sustained-release implants were made according to the method described in Example 1, but the anti-cancer active ingredients contained were one of the following:

[0088] (A) 1% gefitinib and 99% polylactic acid;

[0089] (B) 5% gefitinib and 95% polylactic acid;

[0090] (C) 10% gefitinib and 90% polylactic acid;

[0091] (D) 15% gefitinib and 85% polylactic acid;

[0092] (E) 20% gefitinib and 80% polylactic acid.

Embodiment 3

[0094]Put the weighed (80mg) sustained-release excipient (PLGA with a molecular weight of 15000-25000, 50:50) into the container, add a certain amount of organic solvent to dissolve and mix (subject to full dissolution), then add 20mg of Gefid Tini, re-shake well and dry in vacuo to remove organic solvents. The dried solid composition is shaped immediately, subpackaged and sterilized by radiation to obtain a slow-release implant containing 20% ​​gefitinib. The release time of the slow-release implant in physiological saline in vitro is 24-30 days, and the release time in mouse subcutaneous is 25-34 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a gefitinib sustained-release implant capability for curing solid tumors, such as lung cancer, esophageal cancer, gastric cancer, liver cancer, breast cancer, ovarian cancer, prostatic cancer, bladder cancer, colon cancer and rectum cancer. The invention is characterized in that: the sustained-release implant comprises gefitinib, sustained-release excipient and a certain amount of sustained-release regulator; the amount of the gefitinib and sustained-release excipient is sufficient to control cancer; the sustained-release excipient is mainly one or the combination of the copolymer of glycolic acid and hydroxyacetic acid, polifeprosan, poly (L-lactide-co-ethyl phosphate) and poly (L-lactide-co-propyl phosphate); the gefitinib can be released slowly into part of the tumor during the degradation and adsorption, significantly reducing the systemic toxicity and sustaining the effective medicine concentration simultaneously. The invention has the advantages that: the systemic toxicity of gefitinib can be significantly reduced; the effective medicine concentration can be improved selectively at part of the tumor, and the therapeutic effects of non-operative treatments such as chemotherapeutic drugs and radiotherapy can be reinforced.

Description

(1) Technical field [0001] The invention relates to a gefitinib slow-release implant for treating solid tumors, belonging to the technical field of medicines. (2) Background technology [0002] In the past few decades, although the research on cancer has made great progress, its mortality rate is still in the forefront of various common causes of death. The latest data show that in 2006, 3 million people died of cancer in my country. Due to the impact of environmental pollution and bad eating habits, the incidence of cancer is increasing year by year and showing a younger trend. Statistics show that in less than 20 years, the incidence of cancer in my country has increased by 69%, and the death rate has increased by 29.4%. According to the latest statistics from the World Health Organization, the global cancer incidence rate will increase by 50% by 2020, and the number of patients will increase to 15 million. It is estimated that 4 million people will die of cancer every ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K31/5377A61K47/34A61P35/00
Inventor 孙娟杲伟
Owner JINAN SHUAIHUA PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com